Atopic and non-atopic allergic disorders: Current insights into the possible involvement of free immunoglobulin light chains

Clinical and Experimental Allergy

Volumn 39, Issue 1, 2009, Pages 33-42

  Groot Kormelink, T ^a   Thio, M ^a   Blokhuis, B R ^a   Nijkamp, F P ^a   Redegeld, F A ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Asthma; Atopic; Dermatitis; Food allergy; Immunoglobulin free light chain; Non atopic; Rhinitis

Indexed keywords

ANTIHISTAMINIC AGENT; BIOLOGICAL MARKER; CROMOGLYCATE DISODIUM; F 991; IMMUNOGLOBULIN E; IMMUNOGLOBULIN LIGHT CHAIN; MEPOLIZUMAB; OMALIZUMAB; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ATOPIC DERMATITIS; ATOPY; COMPETITIVE INHIBITION; DERMATITIS; FOOD ALLERGY; HOUSE DUST ALLERGY; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; NOTE; PEANUT ALLERGY; PREVALENCE; PRICK TEST; PRIORITY JOURNAL; PROTEIN FUNCTION;

ASTHMA; DERMATITIS; FOOD HYPERSENSITIVITY; HUMANS; HYPERSENSITIVITY; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN LIGHT CHAINS; RHINITIS;

EID: 58149229537     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2008.03135.x     Document Type: Note

References (105)

1. Pawankar R, Baena-Cagnani CE, Bousquet J et al. State of the world allergy report 2008: allergy and chronic respiratory diseases. WAO J 2008 (Suppl. 1) : S4 17.
2. Bloomfield SF, Stanwell-Smith R, Crevel RW, Pickup J. Too clean, or not too clean: the hygiene hypothesis and home hygiene. Clin Exp Allergy 2006 36 : 402 25.
3. Rook GA. The hygiene hypothesis and the increasing prevalence of chronic inflammatory disorders. Trans R Soc Trop Med Hyg 2007 101 : 1072 4.
4. Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008 49 : 7 19.
5. Theoharides TC, Kalogeromitros D. The critical role of mast cells in allergy and inflammation. Ann NY Acad Sci 2006 1088 : 78 99.
6. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 2008 8 : 205 17.
7. von Bubnoff D, Novak N, Kraft S, Bieber T. The central role of FcepsilonRI in allergy. Clin Exp Dermatol 2003 28 : 184 7.
8. Malbec O, Daeron M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol Rev 2007 217 : 206 21.
9. Eigenmann PA. The spectrum of cow's milk allergy. Pediatric allergy and immunology: official publication of the European Society of Pediatric. Allergy Immunol 2007 18 : 265 71.
10. Bock SA. Prospective appraisal of complaints of adverse reactions to foods in children during the first 3 years of life. Pediatrics 1987 79 : 683 8.
11. Sampson HA. Update on food allergy. J Allergy Clin Immunol 2004 113 : 805 19.
12. Forbes EE, Groschwitz K, Abonia JP et al. IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med 2008 205 : 897 913.
13. Chehade M. IgE and non-IgE-mediated food allergy: treatment in 2007. Curr Opin Allergy Clin Immunol 2007 7 : 264 8.
14. Saito H. Much atopy about the skin: genome-wide molecular analysis of atopic eczema. Int Arch Allergy Immunol 2005 137 : 319 25.
15. Sicherer SH, Leung DY. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects. J Allergy Clin Immunol 2007 119 : 1462 9.
16. Alenius H, Laouini D, Woodward A et al. Mast cells regulate IFN-gamma expression in the skin and circulating IgE levels in allergen-induced skin inflammation. J Allergy Clin Immunol 2002 109 : 106 13.
17. Navi D, Saegusa J, Liu FT. Mast cells and immunological skin diseases. Clin Rev Allergy Immunol 2007 33 : 144 55.
18. Obara W, Kawa Y, Ra C, Nishioka K, Soma Y, Mizoguchi M. T cells and mast cells as a major source of interleukin-13 in atopic dermatitis. Dermatology 2002 205 : 11 7.
19. Horsmanheimo L, Harvima IT, Jarvikallio A, Harvima RJ, Naukkarinen A, Horsmanheimo M. Mast cells are one major source of interleukin-4 in atopic dermatitis. Br J Dermatol 1994 131 : 348 53.
20. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003 112 : 252 62.
21. Flohr C, Johansson SG, Wahlgren CF, Williams H. How atopic is atopic dermatitis? J Allergy Clin Immunol 2004 114 : 150 8.
22. Bardana EJ. Immunoglobulin E- (IgE) and non-IgE-mediated reactions in the pathogenesis of atopic eczema/dermatitis syndrome (AEDS). Allergy 2004 59 (Suppl. 78) : 25 9.
23. Chen L, Overbergh L, Mathieu C, Chan LS. The development of atopic dermatitis is independent of Immunoglobulin E up-regulation in the K14-IL-4 SKH1 transgenic mouse model. Clin Exp Allergy 2008 38 : 1367 80.
24. Brenninkmeijer EE, Spuls PI, Legierse CM, Lindeboom R, Smitt JH, Bos JD. Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol 2008 58 : 407 14.
25. Schmid-Grendelmeier P, Simon D, Simon HU, Akdis CA, Wuthrich B. Epidemiology, clinical features, and immunology of the "intrinsic" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001 56 : 841 9.
26. Lenchner KI, Ditto AM. Idiopathic anaphylaxis. Allergy Asthma Proc 2004 25 : S54 6.
27. Ditto AM, Harris KE, Krasnick J, Miller MA, Patterson R. Idiopathic anaphylaxis: a series of 335 cases. Ann Allergy Asthma Immunol 1996 77 : 285 91.
28. Global, Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2006.
29. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000 161 : 1720 45.
30. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008 31 : 143 78.
31. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006 368 : 804 13.
32. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003 139 : 359 70.
33. Tattersfield AE, Knox AJ, Britton JR, Hall IP. Asthma. Lancet 2002 360 : 1313 22.
34. Humbert M, Menz G, Ying S et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999 20 : 528 33.
35. Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? Thorax 1999 54 : 268 72.
36. Pearce N, Douwes J, Beasley R. Is allergen exposure the major primary cause of asthma? Thorax 2000 55 : 424 31.
37. Beasley R, Pekkanen J, Pearce N. Has the role of atopy in the development of asthma been over-emphasized? Pediatr Pulmonol 2001 23 (Suppl.) : 149 50.
38. Comi AL, Tedeschi A, Lorini M, Miadonna A. Novel clinical and serological aspects in non-allergic asthma. Respir Med 2007 101 : 2526 33.
39. Humbert M, Grant JA, Taborda-Barata L et al. High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 1996 153 : 1931 7.
40. Humbert M, Durham SR, Ying S et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996 154 : 1497 504.
41. Humbert M, Durham SR, Kimmitt P et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 1997 99 : 657 65.
42. Jayaratnam A, Corrigan CJ, Lee TH. The continuing enigma of non-atopic asthma. Clin Exp Allergy 2005 35 : 835 7.
43. Ying S, Meng Q, Zeibecoglou K et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J Immunol 1999 163 : 6321 9.
44. Ying S, Humbert M, Barkans J et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+and CD8+T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997 158 : 3539 44.
45. Amin K, Ludviksdottir D, Janson C et al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR group. Am J Respir Crit Care Med 2000 162 : 2295 301.
46. Ali FR, Kay AB, Larche M. Airway hyperresponsiveness and bronchial mucosal inflammation in T cell peptide-induced asthmatic reactions in atopic subjects. Thorax 2007 62 : 750 7.
47. Bentley AM, Menz G, Storz C et al. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis 1992 146 : 500 6.
48. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002 346 : 1699 705.
49. Truyen E, Coteur L, Dilissen E et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax 2006 61 : 202 8.
50. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC Jr. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992 146 : 109 15.
51. Romanet-Manent S, Charpin D, Magnan A, Lanteaume A, Vervloet D. Allergic vs nonallergic asthma: what makes the difference? Allergy 2002 57 : 607 13.
52. Gould HJ, Sutton BJ, Beavil AJ et al. The biology of IgE and the basis of allergic disease. Annu Rev Immunol 2003 21 : 579 628.
53. Takhar P, Corrigan CJ, Smurthwaite L et al. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol 2007 119 : 213 8.
54. Ying S, Humbert M, Meng Q et al. Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. J Allergy Clin Immunol 2001 107 : 686 92.
55. Powe DG, Jagger C, Kleinjan A, Carney AS, Jenkins D, Jones NS. 'Entopy': localized mucosal allergic disease in the absence of systemic responses for atopy. Clin Exp Allergy 2003 33 : 1374 9.
56. Bousquet J, Cabrera P, Berkman N et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005 60 : 302 8.
57. Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005 60 : 309 16.
58. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005 115 : 459 65.
59. Avila PC. Does anti-IgE therapy help in asthma? Efficacy and controversies. Annu Rev Med 2007 58 : 185 203.
60. Salvi SS, Babu KS. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 2000 342 : 1292 3.
61. Hamelmann E, Cieslewicz G, Schwarze J et al. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med 1999 160 : 934 41.
62. Kraneveld AD, van der Kleij HP, Kool M et al. Key role for mast cells in nonatopic asthma. J Immunol 2002 169 : 2044 53.
63. Mehlhop PD, van de Rijn M, Goldberg AB et al. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc Natl Acad Sci USA 1997 94 : 1344 9.
64. Oettgen HC, Martin TR, Wynshaw-Boris A, Deng C, Drazen JM, Leder P. Active anaphylaxis in IgE-deficient mice. Nature 1994 370 : 367 70.
65. Yu M, Tsai M, Tam SY, Jones C, Zehnder J, Galli SJ. Mast cells can promote the development of multiple features of chronic asthma in mice. J Clin Invest 2006 116 : 1633 41.
66. International, International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. Allergy 1994 49 : 1 34.
67. Grossman J. One airway, one disease. Chest 1997 111 : 11S 6S.
68. Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol 2003 111 : 1171 quiz 1184.
69. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 : S147 334.
70. van Rijswijk JB, Blom HM, Fokkens WJ. Idiopathic rhinitis, the ongoing quest. Allergy 2005 60 : 1471 81.
71. Salib RJ, Harries PG, Nair SB, Howarth PH. Mechanisms and mediators of nasal symptoms in non-allergic rhinitis. Clin Exp Allergy 2008 38 : 393 404.
72. Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy 2006 61 : 693 8.
73. Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999 104 : 301 4.
74. Molgaard E, Thomsen SF, Lund T, Pedersen L, Nolte H, Backer V. Differences between allergic and nonallergic rhinitis in a large sample of adolescents and adults. Allergy 2007 62 : 1033 7.
75. Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol 2001 86 : 494 quiz 507-498.
76. Fokkens WJ. Thoughts on the pathophysiology of nonallergic rhinitis. Curr Allergy Asthma Rep 2002 2 : 203 9.
77. Zacharasiewicz A, Douwes J, Pearce N. What proportion of rhinitis symptoms is attributable to atopy? J Clin Epidemiol 2003 56 : 385 90.
78. Powe DG, Huskisson RS, Carney AS, Jenkins D, Jones NS. Evidence for an inflammatory pathophysiology in idiopathic rhinitis. Clin Exp Allergy 2001 31 : 864 72.
79. Berger G, Goldberg A, Ophir D. The inferior turbinate mast cell population of patients with perennial allergic and nonallergic rhinitis. Am J Rhinol 1997 11 : 63 6.
80. Blom HM, Godthelp T, Fokkens WJ et al. Mast cells, eosinophils and IgE-positive cells in the nasal mucosa of patients with vasomotor rhinitis. An immunohistochemical study. Eur Arch Otorhinolaryngol 1995 252 (Suppl. 1) : S33 9.
81. van Rijswijk JB, Blom HM, KleinJan A, Mulder PG, Rijntjes E, Fokkens WJ. Inflammatory cells seem not to be involved in idiopathic rhinitis. Rhinology 2003 41 : 25 30.
82. Carney AS, Powe DG, Huskisson RS, Jones NS. Atypical nasal challenges in patients with idiopathic rhinitis?: more evidence for the existence of allergy in the absence of atopy. Clin Exp Allergy 2002 32 : 1436 40.
83. Blom HM, Godthelp T, Fokkens WJ, KleinJan A, Mulder PG, Rijntjes E. The effect of nasal steroid aqueous spray on nasal complaint scores and cellular infiltrates in the nasal mucosa of patients with nonallergic, noninfectious perennial rhinitis. J Allergy Clin Immunol 1997 100 : 739 47.
84. KleinJan A, Vinke JG, Severijnen LW, Fokkens WJ. Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients. Eur Respir J 2000 15 : 491 7.
85. Smurthwaite L, Walker SN, Wilson DR et al. Persistent IgE synthesis in the nasal mucosa of hay fever patients. Eur J Immunol 2001 31 : 3422 31.
86. Takhar P, Smurthwaite L, Coker HA et al. Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol 2005 174 : 5024 32.
87. Huggins KG, Brostoff J. Local production of specific IgE antibodies in allergic-rhinitis patients with negative skin tests. Lancet 1975 2 : 148 50.
88. Redegeld FA, van der Heijden MW, Kool M et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med 2002 8 : 694 701.
89. van Houwelingen AH, Kaczynska K, Kraneveld AD, Kool M, Nijkamp FP, Redegeld FA. Topical application of F991, an immunoglobulin free light chain antagonist, prevents development of contact sensitivity in mice. Clin Exp Allergy 2007 37 : 270 5.
90. Kraneveld AD, Kool M, van Houwelingen AH et al. Elicitation of allergic asthma by immunoglobulin free light chains. Proc Natl Acad Sci USA 2005 102 : 1578 83.
91. Shapiro AL, Scharff MD, Maizel JV, Uhr JW. Synthesis of excess light chains of gamma globulin by rabbit lymph node cells. Nature 1966 211 : 243 5.
92. Hannam-Harris AC, Smith JL. Free immunoglobulin light chain synthesis by human foetal liver and cord blood lymphocytes. Immunology 1981 43 : 417 23.
93. Hannam-Harris AC, Smith JL. Induction of balanced immunoglobulin chain synthesis in free light chain-producing lymphocytes by mitogen stimulation. J Immunol 1981 126 : 1848 51.
94. Thio M, Blokhuis BR, Nijkamp FP, Redegeld FA. Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. Trends Pharmacol Sci 2008 29 : 170 4.
95. Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 2001 158 : 1859 66.
96. VanEsch EC, Schouten B, Blokhuis B et al. Anti-CD25 treatment in a mouse model for cow's milk allergy modifies the acute skin response form IgE- into Ig free light chain-dependent. Allergy 2008 63 : 181.
97. Rijnierse A, Redegeld FA, van der Heiden MW, Blokhuis BRJ, Nijkamp FP, Kraneveld AD. Immunoglobulin free light chain: a new immunological factor in IBD. Gastroenterology 2005 128 (Suppl. 2).
98. Zar S, Kumar D, Kumar D. Role of food hypersensitivity in irritable bowel syndrome. Minerva Med 2002 93 : 403 12.
99. Sediva A, Kayserova J, Vernerova E. Increase in immunoglobulin free light chains in children with atopic dermatitis. Allergy 2008 63 : 157.
100. Gottenberg JE, Aucouturier F, Goetz J et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 2007 66 : 23 7.
101. Rinker II. JR, Trinkaus K, Cross AH. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006 67 : 1288 90.
102. Presslauer S, Milosavljevic D, Brucke T, Bayer P, Hubl W. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 2008 doi :.
103. Nakano T, Takahashi H, Miyazaki S et al. Antigen-specific free immunoglobulin light-chain antibodies: could it be a new diagnostic marker for patients with allergy? Clin Biochem 2006 39 : 955 9.
104. van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol 2006 533 : 319 26.
105. Katzmann JA, Clark RJ, Abraham RS et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002 48 : 1437 44.